The mechanism of axon degeneration is incompletely understood. A recent study demonstrates that transgenic expression of bacterial nicotinamide adenine mononucleotide (NMN) in zebrafish and mice, which decreases NMN levels by converting it to NaMN, protects against axon degeneration.
Axon degeneration is a major contributor to the pathology of several neurological disorders, including Alzheimer's disease, Parkinson's disease, traumatic axonal injury, and chemotherapyinduced peripheral neuropathy [1, 2] . Genetic studies support the notion that preserving axon integrity and function is a viable therapeutic strategy for many of these neurological disorders [1, 2] . Understanding the mechanism of axon degeneration is, of course, crucial for this endeavor. In a recent issue of Current Biology, a study by Di Stefano et al. presents data supporting a new model for axon degeneration [3] .
Insights into the mechanism of axon degeneration have been obtained from in vitro and in vivo experimental models of this process, namely the severing of axons from their cell bodies (axotomy), resulting in Wallerian degeneration. The fortuitous discovery of the Slow Wallerian degeneration (Wld S ) mouse mutant, in which severed axons could survive for long periods of time (weeks versus two days) [4] , suggested that axon degeneration was not a passive process, but rather an active process initiated within axons. Freeman and colleagues provided the first direct evidence for an axon-initiated death pathway, showing that genetic ablation of sterile alpha, armadillo repeat, and TIR domain protein 1 (SARM1) in flies and mice potently protects against Wallerian degeneration [5] . Wld S expression [6] [7] [8] significantly delayed degeneration compared to wild-type SCG axons. These results support the notion that the axon-protective effects of NMNd in vivo are neuron-specific; future studies using nervous system-specific NMNd expression would help corroborate these results. Mice lacking NMNAT2 exhibit severe axon growth defects and die perinatally [14] , and these defects are rescued either by expressing Wld S or knocking out SARM1 [18] . This suggests that the observed defects in NMNAT2 knockout Axotomy results in the rapid degradation of NMNAT2, resulting in an increase in its substrate, nicotinamide adenine mononucleotide (NMN). SARM1, downstream (or in a parallel pathway) of NMNAT2 loss, is activated, which leads to axon degeneration. The axon-protective effects of NMNd may be due to lowering NMN levels by using it as a substrate for the synthesis of NaMN.
Current Biology 27, R294-R317, April 24, 2017 R311 (Figure 1 ). However, a recent study by Milbrandt and colleagues showed that boosting NMN levels by overexpressing NAMPT actually protects against Wallerian degeneration, albeit not as efficiently as NMNd [19] . Moreover, they showed that elevating NMN levels (by expressing a bacterial enzyme that converts NaMN back to NMN) in the context of NMNd expression does not ameliorate the protective effects of NMNd. It is important to note that both of these conditions also substantially increase NAD + levels. , which is dependent on SARM1 [17] . This rise in Ca 2+ immediately precedes axon fragmentation. Therefore, one possibility is that NMN binds to a yet unidentified protein, the binding of which causes Ca 2+ release from internal stores in axons and subsequent axon degeneration. Another possibility is that NMN inhibits the activity of an NAD + utilizing enzyme (e.g. PARP, sirtuin) that is required to maintain axon viability. Indeed NMN can inhibit the activity of the bacterial ADP-ribosyltransferase diphtheria toxin [20] , which is structurally and functionally related to mammalian PARPs (PARP1-17 in humans). This inhibition is competitive with NAD + ; therefore, when NAD + levels decrease following axotomy, inhibition by NMN might be more prominent. Understanding the mechanism by which supraphysiological levels of NMN cause axon degeneration is critical for demonstrating that NMN is indeed a pro-axon degenerative molecule. Lastly, the NMNd mice developed in the current study will be useful for evaluating the potential role of NMN as a pro-axon degenerative molecule in neurological disorders, which could lead to the development of novel therapeutics for these disorders.
